Comparative Pharmacology
Head-to-head clinical analysis: MODURETIC 5 50 versus ZESTORETIC.
Head-to-head clinical analysis: MODURETIC 5 50 versus ZESTORETIC.
MODURETIC 5-50 vs ZESTORETIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination diuretic: amiloride blocks epithelial sodium channels (ENaC) in distal tubule, inhibiting sodium reabsorption and potassium excretion; hydrochlorothiazide inhibits sodium-chloride symporter in distal convoluted tubule, increasing sodium, chloride, and water excretion.
Combination of lisinopril (ACE inhibitor) and hydrochlorothiazide (thiazide diuretic). Lisinopril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, decreasing vasoconstriction and aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in distal convoluted tubule, increasing diuresis and reducing plasma volume.
1 tablet (5 mg amiloride/50 mg hydrochlorothiazide) orally once daily, increased if needed to 2 tablets daily as a single dose or divided doses.
Zestoretic (lisinopril/hydrochlorothiazide) is available in fixed-dose combinations. Typical adult dose: 10 mg/12.5 mg, 20 mg/12.5 mg, or 20 mg/25 mg orally once daily. Maximum dose: lisinopril 80 mg/day, hydrochlorothiazide 50 mg/day.
None Documented
None Documented
HCTZ: 5.6-14.8 hours; amiloride: 6-9 hours. Both prolonged in renal impairment (e.g., creatinine clearance <30 mL/min). Terminal elimination half-life for HCTZ may extend to >20 hours in severe renal disease.
Lisinopril: terminal half-life approximately 12 hours (accumulation half-life 13.8 hours in patients with normal renal function). Hydrochlorothiazide: terminal half-life 5.6–14.8 hours (mean 9.6 hours).
Both components are primarily excreted renally: hydrochlorothiazide (HCTZ) ~70% unchanged in urine; amiloride ~50% unchanged in urine. Minor biliary/fecal elimination (<10% for each).
Lisinopril is excreted unchanged in urine; 100% renal elimination. Hydrochlorothiazide is excreted primarily by the kidney (≥95% as unchanged drug) via tubular secretion.
Category C
Category C
Diuretic
ACE Inhibitor + Diuretic